Profile data is unavailable for this security.
About the company
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS, formerly known as Eczacibasi Ilac Sanayi ve Ticaret A.S., (EIS) is a Turkey-based company active in the pharmaceutical industry through its subsidiaries, affiliates and joint ventures. Its product portfolio consists of drugs for human health, veterinary drugs and personal care products, such as body and facial creams, hair gels, deodorants and various other products. The Company is also engaged in real estate development and construction through its subsidiary, Eczacibasi Gayrimenkul Gelistirme ve Yatirim A.S., formerly known as Eczacibasi Insaat ve Ticaret A.S. Its subsidiaries also include Eczacibasi Ilac Ticaret A.S. (EIT), EHP Eczacibasi Health Care Products Joint Stock Co. (EHP), and Eczacibasi Gayrimenkul Gelistirme ve Yatirim A.S., among others. EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S. is a member of Eczacibasi Group of Companies.
- Revenue in TRY (TTM)7.96bn
- Net income in TRY2.49bn
- Incorporated1951
- Employees1.14k
- LocationEIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret ASBuyukdere Cad. Ali Kaya Sok. No:5 LeventISTANBUL 34394TurkeyTUR
- Phone+90 2 123508000
- Fax+90 2 123717399
- Websitehttps://www.eis.com.tr
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sichuan Huiyu Pharmaceutical Co Ltd | 4.89bn | 661.24m | 25.34bn | 1.36k | 38.32 | 1.41 | -- | 5.18 | 0.3218 | 0.3218 | 2.38 | 8.77 | 0.2222 | 1.06 | 13.03 | 739,518.20 | 2.93 | 10.41 | 3.56 | 12.76 | 83.61 | 89.89 | 13.18 | 21.42 | 2.76 | -- | 0.1296 | 20.54 | -37.92 | 76.37 | -43.86 | -- | 66.72 | -- |
| Shouyao Holdings Co Ltd | 19.55m | -947.54m | 25.47bn | 185.00 | -- | 5.72 | -- | 1,302.95 | -1.31 | -1.31 | 0.0271 | 6.17 | 0.0036 | 0.2578 | 1.35 | 21,779.19 | -17.49 | -37.24 | -19.17 | -42.63 | 95.40 | 96.03 | -4,847.44 | -2,251.77 | 7.47 | -- | 0.0093 | -- | 186.18 | -23.51 | -6.76 | -- | 34.59 | -- |
| Pacira Biosciences Inc | 23.67bn | 2.18bn | 25.65bn | 711.00 | 13.87 | 0.8507 | 5.43 | 1.08 | 1.17 | 1.17 | 12.34 | 19.07 | 0.4329 | 1.83 | 6.77 | 970,900.10 | 3.99 | 3.35 | 4.26 | 3.98 | 74.05 | 72.63 | 9.21 | 8.57 | 5.70 | -- | 0.4013 | 0.00 | 1.22 | 14.88 | 163.72 | -- | 0.8761 | -- |
| Torii Pharmaceutical Co Ltd | 13.16bn | 1.21bn | 25.79bn | 583.00 | 20.84 | 0.9091 | 19.71 | 1.96 | 186.93 | 186.93 | 2,036.86 | 4,284.47 | 0.4304 | 2.79 | 2.23 | 98,195,540.00 | 3.95 | 6.52 | 4.36 | 7.35 | 44.49 | 49.55 | 9.18 | 17.98 | 5.70 | -- | 0.00 | 24.17 | 11.74 | -2.67 | 4.44 | 28.76 | -20.38 | 20.11 |
| EIS czcbs lc Sn v Fnnsl Ytrmlr Sny v Tcr | 7.96bn | 2.49bn | 26.45bn | 1.14k | 10.62 | 0.6179 | 8.46 | 3.32 | 3.63 | 3.63 | 11.61 | 62.47 | 0.2079 | 3.86 | 6.86 | 6,955,255.00 | 6.50 | 8.49 | 7.05 | 9.06 | 33.66 | 32.94 | 31.29 | 58.23 | 0.9382 | -- | 0.0722 | -- | 86.94 | 56.41 | -8.16 | 62.73 | 141.59 | 31.51 |
| Guizhou Sanli Pharmaceutical Co Ltd | 9.34bn | 1.50bn | 26.50bn | 2.28k | 18.23 | 3.58 | -- | 2.84 | 0.7311 | 0.7311 | 4.59 | 3.72 | 0.7844 | 2.50 | 4.26 | 843,357.60 | 12.76 | 12.39 | 19.35 | 16.72 | 70.14 | 70.45 | 16.27 | 16.31 | 1.52 | -- | 0.2486 | 25.70 | 36.10 | 17.75 | 45.42 | 21.51 | 127.48 | -- |
| Hunan Fangsheng Pharmaceutical Co Ltd | 8.17bn | 1.05bn | 26.67bn | 1.69k | 24.91 | 3.64 | -- | 3.27 | 0.5026 | 0.5026 | 3.87 | 3.44 | 0.5372 | 1.44 | 6.24 | 998,562.10 | 6.67 | 5.39 | 11.80 | 9.37 | 68.22 | 66.91 | 12.43 | 8.95 | 0.472 | 14.06 | 0.3458 | 46.47 | -9.12 | 9.15 | -34.64 | 20.68 | 23.91 | 4.75 |
| Gen Ilac ve Saglik Urnlr Snyi ve Tcrt AS | 12.60bn | 178.31m | 27.68bn | 617.00 | 155.20 | 4.70 | 48.82 | 2.20 | 0.5944 | 0.5944 | 42.00 | 19.62 | 1.68 | 15.72 | 9.78 | 20,256,010.00 | 2.31 | 12.39 | 3.73 | 17.53 | 19.31 | 19.06 | 1.37 | 6.95 | 1.29 | 3.41 | 0.1773 | -- | -23.38 | 47.18 | -28.97 | 147.97 | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Jul 2024 | 5.71m | 0.83% |
| Dimensional Fund Advisors LPas of 30 Apr 2024 | 1.56m | 0.23% |
| BlackRock Advisors (UK) Ltd.as of 04 Jul 2024 | 541.28k | 0.08% |
| BlackRock Fund Advisorsas of 04 Jul 2024 | 430.75k | 0.06% |
| JPMorgan Investment Management, Inc.as of 03 Jul 2024 | 417.75k | 0.06% |
| State Street Global Advisors Ltd.as of 04 Jul 2024 | 395.85k | 0.06% |
| BlackRock Investment Management (UK) Ltd.as of 30 Jun 2024 | 307.22k | 0.05% |
| Charles Schwab Investment Management, Inc.as of 03 Jul 2024 | 222.90k | 0.03% |
| SSgA Funds Management, Inc.as of 03 Jul 2024 | 219.13k | 0.03% |
| Dimensional Fund Advisors Ltd.as of 31 May 2024 | 128.03k | 0.02% |
